63243-76-5

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Amino-5-bromo-benzoic acid ethyl ester is utilized as an intermediate in the pharmaceutical industry for the synthesis of various drugs and medicinal compounds. Its unique structure allows for the development of new therapeutic agents with potential applications in treating a range of diseases and conditions.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, 2-amino-5-bromo-benzoic acid ethyl ester serves as a key intermediate for the synthesis of diverse organic compounds. Its reactivity and functional groups enable the creation of novel molecules with specific properties and applications, contributing to advancements in material science, agrochemicals, and other related areas.
Used in Chemical Research:
2-Amino-5-bromo-benzoic acid ethyl ester is also employed in chemical research as a model compound for studying various reaction mechanisms and exploring new synthetic routes. Its unique structure and reactivity make it an attractive candidate for investigating the properties of related compounds and understanding the underlying principles of chemical reactions.

InChI:InChI=1/C9H10BrNO2/c1-2-13-9(12)7-5-6(10)3-4-8(7)11/h3-5H,2,11H2,1H3

Upstream product

• 75-03-6 ethyl iodide 
• 64-17-5 ethanol 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 87-25-2 2-ethoxycarbonylaniline 

Downstream Products

• 857602-36-9 2-amino-5-mercapto-benzoic acid ethyl ester 
• 120572-40-9 5-Bromo-2-(3-carboxy-propionylamino)-benzoic acid ethyl ester 
• 127510-93-4 5-bromo-2-cyanobenzoic acid ethyl ester 
• 153501-29-2 ethyl N-<4-bromo-2-(ethoxycarbonyl)phenyl>glycinate 
• 137046-56-1 5-Brom-2<(4-ethoxy-1,4-dioxobutyl)amino>benzoesaeureethylester 
• 153501-30-5 ethyl 5-bromo-3-hydroxyindole-2-carboxylate 
• 117324-24-0 5-ethylsulfanyl-2-amino-benzoic acid ethyl ester 
• 304853-89-2 2-(2-amino-5-bromophenyl)-propan-2-ol 
• 84646-91-3 Hydrazide of 2-amino-5-bromo-benzoic acid 

Relevant academic research and scientific papers

Synthesis, biological screening, in silico study and fingerprint applications of novel 1, 2, 4-triazole derivatives

A series of novel 1,2,4 triazole derivatives were synthesized by treating 4-bromo-2-(4H-1,2,4-triazole-3-yl)aniline (4) with different substituted benzene sulfonyl chlorides 5(a-f) and benzyl bromides 7(a-e). IR, 1H-NMR, 13C-NMR, and

Aryl halide and synthesis method and application thereof

The invention discloses a synthesis method of aryl halides (including aryl bromide shown as a formula (2) and aryl iodide shown as a formula (3)). All the systems are carried out in an air atmosphere,visible light is utilized to excite a substrate or a photosensitizer to catalyze the reaction; and in a reaction solvent, when aromatic hydrocarbon shown in the formula (1) and sodium bromide serve as raw materials, aryl bromide shown in the formula (2) is obtained through a reaction under the auxiliary action of an additive (protonic acid); or when aromatic hydrocarbon shown in the formula (1) and sodium iodide are used as raw materials, under the auxiliary action of an additive (protonic acid), aryl iodide shown in the formula (3) is obtained through reaction. The synthesis method has the advantages of cheap and accessible raw materials, simple reaction operation and mild reaction conditions. The method is compatible with the arylamine which is liable to be oxidized. The invention provides a new method for the synthesis of aryl halides, realizes the amplification of basic chemicals aryl halides including aryl bromide shown in the formula (2) and aryl iodide shown in the formula (3),and has wide application prospect and practical value.

Visible-light-promoted oxidative halogenation of (hetero)arenes

Organic halides are critical building blocks that participate in various cross-coupling reactions. Furthermore, they widely exist as natural products and artificial molecules in drugs with important physiological activities. Although halogenation has been well studied, to the best of our knowledge, studies focussing on sensitive systems (e.g.aryl amines) have not been reported. Herein, we describe a compatible oxidative halogenation of (hetero)arenes with air as the oxidant and halide ions as halide sources under ambient conditions (visible light, air, aqueous system, room temperature, and normal pressure). Moreover, this protocol is practically feasible for gram-scale synthesis, showing potential for industrial application.

PDE9 inhibitor and use thereof

The invention belongs to the technical field of medicines, and particularly relates to a PDE9 inhibitor compound shown as a formula (I) or pharmaceutically acceptable salt and isomer thereof, and alsorelates to pharmaceutical preparations, pharmaceutical

RE[N(SiMe3)2]3-Catalyzed Guanylation/Cyclization of Amino Acid Esters and Carbodiimides

The example of rare-earth metal-catalyzed guanylation/cyclization of amino acid esters and carbodiimides is well-established, forming 4(3H)-2-alkylaminoquinazolinones in 65-96% yields. The rare-earth metal amides RE[N(TMS)2]3 (RE = Y, Yb, Nd, Sm, La; TMS = SiMe3) showed high activities, and La[N(TMS)2]3 performed best for a wide scope of the substrates.

ACC INHIBITORS AND USES THEREOF

The present invention provides for compounds of formula I as acetyl-CoA carboxylase (ACC) inhibitors. The ACC inhibitors are useful for the prevention or treatment of metabolic syndrome, including obesity, dyslipidemia and hyperlipidemia in humans. The in

Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABAA α5 inverse agonist series

Through iterative design cycles we have discovered a number of novel new classes where the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine was deemed the most promising GABAA α5 inverse agonist class with potential for cognitive enhanc

Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors

A new series of pyrazole-based factor Xa inhibitors have been identified as part of our ongoing efforts to optimize previously reported clinical candidate razaxaban. Concern over the possible formation of primary aniline metabolites via amide hydrolysis led to the replacement of the primary amide linker between the pyrazole and phenyl moieties with secondary amides. This was accomplished by replacing the aniline with a variety of heterobicycles, of which indolines were the most potent. The indoline series demonstrated subnanomolar factor Xa binding Kis, modest to high selectivity versus other serine proteases, and good in vitro clotting activity. A small number of indoline fXa inhibitors were profiled in a dog pharmacokinetic model, one of which demonstrated pharmacokinetic parameters similar to that of clinical candidate razaxaban.

Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives

The present invention is a compound of formula wherein R1 is halogen or lower alkyl; R2 is hydrogen, lower alkyl, cycloalkyl, —(CH2)m-phenyl, wherein the phenyl ring may be substituted by lower alkoxy, or is —(CH2)m-indolyl; R3 is —C(O)O-lower alkyl, —C(O)OH, or a five membered heteroaromatic group, which rings may be substituted by lower alkyl or cycloalkyl; n is 0, 1 or 2; m is 0, 1 or 2; or a pharmaceutically acceptable acid addition salt thereof. Compound I shows high affinity and selectivity for GALA A α5 receptor binding sites.

Nitrogen containing heterobicycles as factor Xa inhibitors

This invention relates generally to nitrogen containing heterobicycles of formulas A and B: which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.